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Summary: Data collected in the 1993 and 1994 cycles of an international External Quality Assessment (EQA)
programme were cumulatively analysed to evaluate the analytical performance of the methods currently in use for
routine assay of mucinous tumour markers CA 19-9, CA 15-3 and CA 125. On average the between-laboratory
variability was 14.7 and 15.8 CV% for CA 15-3 and CA 125 respectively. For CA 19-9, a markedly worse between-
laboratory variability (on average 27.2 CV%) was found; the agreement of CA 19-9 results worsened in the last
few years when new non-isotopic techniques became available. The variability component attributable to systematic
differences between methods/kits was relatively small for CA 15-3 and CA 125 (17% and 21% of the total variabil-
ity), while it was markedly larger for CA 19-9 (45% of the total variability). The precision of the methods/kits most
often used in the survey ranged from 9.6 to 13.9 CV% for CA 125 and from 10.8 to 14.1 CV% for CA 15-3. For
these two tumour markers the precision of the traditional IRMAs does not appear to be different from that of the
new fully automated non-isotopic techniques. The precision of CA 19-9 methods was on average worse (from 11.9
to 19.2 CV%), even though the precision of the two automated systems was better than that of IRMAs. In conclu-
sion, the results of this study indicate that the between-laboratory agreement for CA 15-3 and CA 125 assays
appears satisfactory, while the CA 19-9 assay shows larger differences between methods and is affected by poorer
precision of kits.
Introduction
Determination of mucinous tumour markers CA 19-9,
CA 15-3 and CA 125, recognized by monoclonal anti-
bodies, is generally considered a useful tool in the moni-
toring of cancer patients (1, 2). The assay of these tu-
mour markers is routinely carried out by many laborato-
ries, and numerous methods/kits have been developed
and are commercially available. Immunoradiometric
(IRMA) techniques with I?5I-labelled antibody as a
tracer were used earlier for the assay of mucinous mark-
ers; more recently non-isotopic immunoassays, based on
antibodies labelled with enzymes, fluorescent dyes or
chemilunünescent compounds have been developed.
The assays performed with these latter .techniques can
also be carried out with fully automated systems.
The increasing number of different methods/kits avail-
able and the large number of samples routinely assayed
prompted the setting up of external quality assessment
(EQA) schemes to evaluate the analytical performance
of the laboratories and of the methods; for this reason
the EQA for carcinoembryonic antigen and a-foetoprot-
ein organized by our Institute and sponsored by CNR
was extended to the mucinous markers (3, 4). Starting
from 1991 the CNR programme joined with the On-
cocheck International EQA organized by Service de Ra-
diopharmacie et Radioanalyse, University of Lyon and
by Cis Biolnternational (5).
Data collected in 1993 and 1994 cycles of Oncocheck
EQA have been cumulatively analysed in this paper to
evaluate the performance of the routinely used methods.
Materials and Methods
Outline of the Oncocheck EQA program
The Oncocheck programme includes, at present, six tumour mark-
ers: -foetoprotein, carcinoembryonic antigen, CA 19-9, CA 15-3,
CA 125 and prostate-specific antigen. The scheme does not sub-
stantially differ from other EQAs (6, 7): participants measure 24
samples every year (2 samples each month); they are asked to per-
form the assay routinely and to return results indicating the
method/kit used; collected results are computer processed by the
organizing centers of Lyon and Pisa; monthly and cumulative (six
month period) reports are prepared and sent back to the partici-
pants. At present, the Oncocheck programme involves more than
250 laboratories of many European countries (mainly in Italy and
France).
Control materials are normal pools with added sera from patients
with high concentrations of tumour markers; control samples (con-
taining all six tumour markers) are prepared from these pools and
freeze-dried.
During an EQA cycle (six month) control samples derived from
the same pool are mailed out in different batches, as hidden repli-
cates, to estimate the reproducibility of the laboratories and of the
kits.
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The present analysis is based on results collected from 48 quality
control samples distributed during the Oncocheck EQA cycles
1993-1994. The 48 samples were prepared from 24 different
pools; 8 pools gave origin to 24 samples (assayed as hidden tripli-
cates), 8 pools gave origin to 16 samples (assayed as hidden dupli-
cates), and 8 pools gave origin to the remaining 8 samples.
Monthly and cumula t ive reports
Results collected from a control sample are included (as a fre-
quency distribution histogram) in the monthly report, together with
the main statistics (mean, median, CV, range) computed from all
data and from data grouped according to the method/kit. The aim
of this report is to allow comparison of the result produced by a
laboratory for a single EQA sample with those produced by all
other participants and in particular by the users of the same
method/kit.
An end-of-period or cumulative report is also prepared to provide
the participant with an estimate of bias and precision based on the
results of all control samples assayed during the control cycle. In
addition, this cumulative report contains estimates of the analytical
performance of the kits most used in the survey; details of monthly
and cumulative reports were described previously (8).
The agreement of CA 125 and CA 15-3 assays can be
considered satisfactory, since it is similar to or smaller
than the between-laboratory variabilities observed for
the other three tumour markers included in the On-
cocheck EQA (18.6 CV% for carcinoembryonic antigen,
15.3% for a-foetoprotein, 36.0%· for prostate-specific
antigen).
In contrast, the between^-laboratory variability found in
CA 19-9 is markedly worse (on average 27.2 CV%); in
addition the CVs of CA 19-9 results observed in the 48
control samples differ greatly from each other (ranging
from 18.1% to 34.3%) depending on the control material
assayed; this behaviour is at variance with that observed
for CA 15-3 and CA 125 which showed a narrower
range of CVs.
The differences in the variabilities observed in the three
tumour markers were further investigated by using the
Data analysis
The following estimates of variability are used in the evaluation of
EQA data and are here briefly recalled; for more details see 1. c. (8).
Total variability
The average total variability observed during the whole EQA
period (also referred to as between-laboratory agreement or be-
tween-laboratory variability) is estimated by averaging the CVs
computed from the results of each control sample; this measure-
ment of variability includes both systematic between-kit differences
and differences introduced by the laboratories.
Between-kit and within-fat components
A statistical technique (one-factor ANOVA with components of
variance estimation (9, 10)) is used to split the total variability into
two components: the between-kit variability which accounts for the
systematic differences in results produced by different kits, and the
within-kit variability which represents the precision of "the
average kit".
Kit precision
The precision of the kits is estimated by averaging the CVs of
the results produced by participants for the same control material
(assayed in different laboratories and on different occasions by the
users of the same kit); the reported average CV is therefore an
estimate of the between-laboratory, between-assay precision
achieved by the kit during the whole EQA period.
Results and Comments
Total variabil i ty and within-kit and between-
kit components
The total variabilities for CA 15-3, CA 19-9 and CA 125
observed in 48 quality control samples are shown in fig-
ure 1 as between-laboratory precision profiles; on
average a between-laboratory agreement of 14.7 and
15.8 CV% was observed for CA 15-3 and CA 125
respectively. For CA 125 the variability increases in con-
trol samples in the low concentration range (< 17
kIU/1).
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Fig. I Total variability (between^laboratory agreement) observed
in 48 QC samples plotted against the respective consensus means
for CA 15-3, CA 19-9 and CA 125. Data refer to control samples
distributed in the Oncocheck programme* (from December 1992 to
November 1994).
Pilo et al.: Performance of immunoassay for CA 19-9, CA 15-3 and CA 125 147
Anova technique to evaluate the between-kit and within-
kit components of total variability. The between-kit
component (which reflects the systematic differences in
results produced by different methods/kits) is relatively
small for CA 15-3 and CA 125 (this component ac-
counts only for 17% and 21% of the total variability),
while it is markedly larger for CA 19-9 (45% of the
total variability). The large between-kit differences in
CA 19-9 can be clearly appreciated from figure 2 in
which histograms of the results produced by four dif-
ferent methods are reported and compared with the dis-
tribution of all data.
The within-kit variability (an estimate of the precision
of the "average" kit) was found to be worse in CA 19-
9 (20.1 CV%) than in CA 15-3 (13.4 CV%) and CA 125
(14.0 CV%).
Between-kit comparison
CA 75-5
Results collected in the EQA programme were mainly
produced by 5 different methods/kits: 3 IRMAs (Cento-
cor, CIS and Byk-Sangtec) and 2 non-isotopic, fully au-
tomated techniques (LIA-mat S300 Byk-Sangtec, Enzy-
mun Test ES Boehringer Mannheim). The results pro-
duced by these 5 methods on control samples were com-
pared by regression analysis (versus IRMA Centocor)
(tab. 1). The results of the 5 different methods appear
well correlated (R = 0.98-0.99) and the differences in
concentration are on average 10% or less.
CA 125
Results collected in the EQA were mainly produced by
7 different methods/kits: 4 IRMAs (Centocor, CIS, Sorin
and Byk-Sangtec) and 3 non-isotopic, fully automated
techniques (LIA-mat S300 Byk-Sangtec, Enzymun Test
ES Boehringer and IMX Abbott).
The results produced by these 7 methods on control
samples were compared by regression analysis (versus
IRMA Centocor) (tab. 1). The results from the 7 dif-
ferent methods appear well correlated (R = 0.98-1.00);
the differences in concentration are higher than those
observed for CA 15-3; for samples with concentrations
> 100 kIU/1, three of the methods (IRMA and LIA Byk-
Sangtec, Enzymun Test ES Boehringer) give results
higher than IRMA Centocor.
CA 19-9
The majority of results collected in the EQA were pro-
duced by 8 different method/kits: 4 IRMAs (Centocor,
CIS, Sorin and Byk-Sangtec) and 4 non-isotopic, fully
automated techniques (LIA-mat S300 Byk-Sangtec
which uses a luminescent tracer); and 3 systems (Enzy-
CA19-9[klU/l]
Fig. 2 Frequency distribution histograms of results (identified by a) IRMA Cenlocor
the laboratory code) produced by four different methods/kits assay- b) IMX Abbott
ing CA 19-9 in the control sample B1401 distributed in January c) IRMA Cis
1994: d) Enzymun Boehringer
The distribution of all results is represented by the hatched histogram
(consensus mean = 43.2 kIU/1, CV = 27.7%, n = 181).
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mean = 41.6WU/1, n = 13;
mean = 66.4 kIU/1, n = 17;
mean = 40.1 klU/K n = 86;
mean - 26.6 klU/K n = 18.
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mun Test ES Boehringer, IMX Abbott and Cobas Core
Roche, based on the use of enzymes as tracer). Method
comparison based on regression analysis is reported in
table 2; regression was performed versus IRMA Cento-
cor because this assay was the first routinely used. Re-
sults of the 4 IRMAs appear well correlated (R = 0.98-
0.99) with relatively small differences in measured con-
centrations; results from the luminescent method L1A-
Tab. 1 CA 15-3 and CA 125: regression analysis between the method/kits most commonly used in
the survey.
X
CA 15-3
IRMA Centocor0
IRMA Centocor
IRMA Centocor
IRMA Centocor
CA 125
IRMA Centocor1
IRMA Centocor
IRMA Centocor
IRMA Centocor
IRMA Centocor
IRMA Centocor .
y
IRMACis
LIA Byk Sangtec
IRMA Byk Sangtec
Enzymun Test Boehringer
IRMA Sorin
IRMACis
IRMA Byk Sangtec
LIA Byk Sangtec
IMX Abbott
Enzymun Test Boehringer
Slope
0.83
1.02
0.92
0.87
1.00
0.99
1.34
1.30
1.12
1.20
Intercept
(kIU/1)
+2.8
+ 1.0
+0.4
+ 1.2
+0.4
-1.0
-9.0
-9.9
-5.3
-6.2
R
0.99
0.99
0.98
0.98
1.00
0.99
0.99
0.99
0.98
0.98
a
 Regression of the most commonly method/kits vs IRMA Cento-
cor; the concentration range of the samples was 15 — 138 kIU/1 for
CA 15-3 and 10-153 kIU/1 for Ca 125 (measured by IRMA Cento-
cor).
Tab. 2 CA 19-9: regression analysis between the method/kits most commonly used in the survey.
X
IRMA Centocor3
IRMA Centocor
IRMA Centocor
IRMA Centocor
IRMA Centocor
IRMA Centocor
IRMA Centocor
IMX Abbottb
IMX Abbott
y
IRMA Sorin
IRMA Byk Sangtec
IRMACis
LIA Byk Sangtec
IMX Abbott
IEMA Roche
Enzymun Test Boehringer
IEMA Roche
Enzymun Test Boehringer
Slope
0.86
1.13
0.75
1.25
1.25
1.47
0.63
1.21
0.55
Intercept
(kIU/1)
+3.1
-2.0
+6.1
-4.5
+8.7
+4.3
+8.8
-9.4
-2.0
R
0.99
0.99
0.98
0.96
0.92
0.88
0.81
0.98
0.97
a
 regression of the most commonly used method/kits vs. IRMA
Centocor; the concentration range of the samples was 10-240
kIU/1 (measured by IRMA Centocor).
b
 regression among the three method/kits using enzymes as tracer:
IMX Abbott (x), IEMA Roche and Enzymun Test Boehringer (y).
Tab. 3 Comparison of CA 19-9 results (kIU/1) produced by the 8 most popular method/kits3).
Pool
P017C)
P030
P021
P027
P016
P034
P029
P023
P022
P014
IRMA
Centocor
(12-15)b)
17.0
33.2
39.4
43.8
73.6
104
106
111
208
232
IRMA
Sorin
(10-12)
16.3
30.7
37.1
43.3
70.5
98.1
88.0
102
184
219
IRMA
Byk
(12-15)
18.0
37.4
37.5
49.9
70.3
121
119
115
246
250
IRMA
Cis
(80-90)
14.0
28.4
38.0
38.5
70.0
113
82.7
97.6
153
202
LIA
Byk
(8-10)
17.8
38.2
35.9
55.0
83.5
121
135
125
280
297
IMX
Abbott
(18-24)
25.6
37.8
77.4
64.1
141
139
110
163
232
402
IEMA
Roche
(8-10)
26.2
37.5
105
53.3
157
129
113
205
280
488
Enzymun
Boehringer
(18-22)
15.9
18.2
54.7
27.0
89.3
81.7
53.4
94.6
99.2
238
a) mean results from 10 pools are reported in this table as exam-
ples; the behaviour of the different kits on these pools is representa^
tive of that observed in all the control samples circulated in the
EQA.
b) number of users of the method/kit in the Oncocheck program.
c) each pool was sent to the participants;on 2-3 occasions as a
hidden replicate sample.
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mat are also well correlated with IRMAs (R = 0.98).
Results of the 3 enzymatic methods are, in contrast,
scarcely correlated with IRMAs (R = 0.83-0.93);
their results however are well correlated with each
other (0.97-0.99 versus IMX Abbott), even though
the concentrations found by Enzymun Test are, in all
cases, about 50% lower than those found by IMX
or Roche.
The poor correlation of enzymatic techniques versus IR-
MAs can be appreciated in more detail from the mean
concentrations found in 10 control pools (representative
of all control materials distributed during the EQA) re-
ported in table 3. It can be seen that different results are
produced by enzymatic methods and IRMAs, depending
on the different control material assayed. This behaviour
is exemplified by comparison of 3 pairs of pools shown
in figure 3. In pool P030 and in pool P021 the four
IRMAs and the luminescent method measure similar
concentrations, whereas according to the 3 enzymatic
methods the concentration in pool P021 is almost double
that of pool P030. Similar behaviour is observed for
pool P029 and P023. On the other hand, different behav-
100-
Fig. 3 Mean results produced by the 8 most used methods/kits
assaying 6 pools distributed in the EQA period; direct comparisons
of 3 pairs of pools (P030 vs P021 top panel; P016 vs P034 middle
panel; P029 vs P023 bottom panel) shows the different behaviour
of isotopic and enzymatic immunoassays with different control ma-
terials.
iour is observed in pools P016 and P034: the three enzy-
matic methods measure similar concentrations, while
IRMAs and LIA find in pool P034 a concentration ap-
proximately 30-40% higher than that measured in
pool P016.
The reasons for these discrepancies are unclear; it is,
however, conceivable that different method/kits for CA
19-9, even though based on the same monoclonal
antibody (1116-NS 19-9, from Centocor) and the same
antigen for standard preparation (also from Centocor),
may show a different degree of specificity against CA
19-9 determinants, due to differences in the tracer, in
the solid-phase preparation and/or in the experimental
assay conditions (pH, time and temperature of the
antigen/antibody reaction). The presence in serum of
different molecular forms of CA 19-9 (11), detected
by the methods/kits with different degree of specificity,
may explain the discrepancies observed in different
control samples. Moreover, it is likely that the specifi-
cities of IRMAs (and of the chemiluminescent assay)
are similar to each other, whereas the three enzymatic
techniques also show specificities similar each other,
but different from those of IRMAs.
This hypothesis explains why determinations of control
samples distributed in the EQA (which probably contain
the different CA 19-9 forms in different ratios) correlate
only if performed by techniques of the same type
(IRMA or IEMA).
Further support for these considerations is provided by
data in figure 4, in which results produced by Abbott
IMX and Enzymun Test Boehringer (both expressed as
fraction of IRMA Centocor) are plotted against the con-
centrations measured by IRMA Centocor; it can be
clearly appreciated that:
1) the two enzymatic methods measure CA 19-9 with
specificity different from IRMA and
2.0 Ί
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CA 19-9 (IRMA Centocor) [klU/l]
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Fig. 4 Mean results found, for the 24 pools distributed during the
EQA period (1993-1994), by users of IMX Abbott (D-D) and
Enzymun Test Boehringer (D—D), compared with results from
IRMA Centocor; data from IMX Abbott and Enzymun Test Boeh-
ringer are expressed as fraction of the corresponding results pro-
duced by IRMA Centocor.
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2) the two enzymatic methods recognize CA 19-9 with
the same specificity; the lower values produced by En-
zymun Test with respect to 1MX can be simply ex-
plained by differences in the calibration.
Precision of the method/kits
The precision of the kits was estimated by averaging the
CVs of results produced by the kit for the same control
material (assayed in different laboratories and on dif-
ferent occasions); therefore the reported average CV can
be considered as an estimate of the between-laboratory
and between-assay precision achieved by the kit during
the whole EQA period.
The precision of the methods/kits most commonly used
in the survey is reported in table 4 for the three tumour
Tab. 4 Average precisions0 (between-laboratory and between-as-
say, CV%) of the most commonly used methods/kits for CA 15-3,
CA 125 and CA 19-9 assays.
Method/kit CA 15-3 CA 125 CA 19-9
Enzymun Test Boehringer
IRMA Centocor
IRMACis
IMX Abbott
IRMA Byk Sangtec
LIA Byk Sangtec
IEMA Roche
IRMA Sorin
10.8
13.1
13.2
-
14.1
12.5
—
—
11.4
10.1
9.6
13.9
11.0
12.8
—
11.3
14.2
19.2
18.8
11.9
16.8
16.1
18.5
18.4
a
 The precisions of the kits were estimated by averaging the CVs
of results produced on the same control material assayed in dif-
ferent laboratories and on different occasions. The samples with
very low concentration (< 17 kIU/1 for the three markers) were
excluded from the computation of the average since their CVs were
considerably higher than those of all other samples.
markers. The CV of the 7 methods for CA 125 assay
ranged from 9.6 to 13.9%, and the CV of the 5 methods
for CA 15-3 assay ranged from 10.8 to 14.1%. For these
two tumour markers the precision of the traditional IR-
MAs does not appear to differ from that of the new fully
automated non-isotopic techniques! On the other hand
the precision of the 8 methods used for CA 19-9 assay
was found on average to be worse (from 11.9 to 19.2
CV%); it is. worth noting that the precision of the auto-
mated systems, Abbott IMX and Enzymun Test ES
Boehringer, is better than that of IRMAs and similar to
that attained in CA 125 and CA 15-3 assays.
Concluding remarks
Analysis of results collected in the EQA for CA 15-3
and CA 125 assays indicates both a satisfactory be-
tween-method agreement and a good kit precision. In
contrast, the CA 19-9 assay appears to be affected by
larger differences between methods and by poorer
precision of kits. The agreement of CA 19-9 results
worsened in the last few years when new non-isotopic
techniques became available and became more widely
used for routine purposes (12). These differences may
arise because new techniques, in particular those using
enzymes as tracer, have different specificities from the
IRMA methods.
The satisfactory standardization observed in control
samples for CA 15-3 and CA 125 does not however
justify over-optimistic conclusions. The possibility can-
not be excluded that, due to the heterogeneity of CA
15-3 and CA 125 and to different proportions of their
isoforms, method agreement may be worse for patient
samples than for control samples.
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Evaluation of the Abbott IMx Ultrasensitive II faTSH Immunometric
Assay in Three European Centres:
A Comparison with Established Commercial Immunometric Assays
for Thyrotropin
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Marie-Paule Bounaud3
1
 Institut fur Klinische Laboratoriumsdiagnostik, Klinikum der Hansestadt Stralsund, Stralsund, Germany
2
 Interne Abteilungen des Krankenhaus der Barmherzigen Brüder, Graz-Eggenberg, Austria
3
 Service Biophysique, Höpital Jean-Bernard, CHU, Poitiers, France
Summary: The Abbott Ultrasensitive II hTSH assay was evaluated in three European centres and its performance
compared with its predecessor and with commercially available kits. A total of 408 individuals was included in the
study (140 euthyroid, 116 hyperthyroid and 86 hypothyroid subjects, as well as 26 patients with non-thyroidal
illness and 30 patients with thyroid cancer). The kit was evaluated for (im)precision and analytical and functional
sensitivity according to ECCLS-Guidelines.
The analytical sensitivity lay between 0.004 and 0.013 mU/1, the mean value being 0.008 mU/1, results being from
12 runs. The functional sensitivity gave a coefficient of variation below 20% at a concentration of 0.05 mU/1 under
routine conditions.
Inter-assay precision was less than 7% at 0.25 mU/1 (range 5.3-6.8%), less than 6% at 6 mU/1 (range 4.0-5.2%)
and less than 9% at 30 mU/1 (range 6.5 — 8.7%). Intra-assay (im)precision was not calculated as the Abbott IMx is
designed to run on singlicate determinations.
Introduction
The aim of the study was to evaluate the new Ultrasensi-
tive II hTSH assay designed for use on the Abbott IMx
by comparing performance with its predecessor and with
three well established commercial immunometric assays
designed to measure thyrotropin in human serum/
plasma samples.
The study was carried out in laboratories in Germany,
France and Austria using an Abbott IMx coupled to a com-
puter for direct data reduction and storage on floppy disks.
The main points examined were the (im)precision (ac-
cording to ECCLS format), the analytical sensitivity and
the functional sensitivity of the assay, the latter using a
panel of seven sera with low thyrotropin-concentrations
common to all centres.
Clinically relevant samples were chosen to compare the
concordance between diagnosis and measured thyrotro-
pin concentration in treated and untreated hypo- and hy-
perthyroid patients, as well as in patients with no evidence
of thyroid disease who acted as euthyroid controls.
Materials and Methods
Kit under examination
The kit under examination was the IMx Ultrasensitive hTSH II,
List number 4B01, Abbott Laboratories, Diagnostics Division, Ab-
bott Park, IL, USA. The test was based on an automated micropar-
ticle immunoenzymometric assay with alkaline phosphatase as la-
bel and 4-methyl umbel liferyl phosphate as substrate. Several lots
of reagents were used in the study, the results, however, being used
without specific reference to the reagent lot, as one aim of the
study was to evaluate under normal laboratory conditions.
Kits used for comparison
BeriLux hTSH - Product No. OCNA, Behringwerke AG, Marburg
a. d. L., Germany. This kit is an immunoluminometric assay based
on coated tube technology and an acridinium derivative as label,
and uses a two point calibration against a lot specific master curve
(0—100 mU/1 thyrotropin), the latter being given into the instru-
ment before using the reagent lot. The euthyroid range was de-
clared by the manufacturer as 0.25-4 mU/1, hyperthyroid patients
being "preponderantly less than 0.1 mU/1" and hypothyroid pa-
tients having concentrations above 5 mU/1. These ranges were eval-
uated from 451 individuals.
DYNOtest TSH, B.R.A.H.M.S. Diagnostica GmbH (formerly
Henning-Berlin), Berlin, Germany. This immunoradiometric assay
is also based on coated tube technology and uses a I25Iodine-label
as tracer. A standard curve consisting of seven points (0.02—80
mU/1 thyrotropin) is set up with each run. The ranges of concentra-
tions given by the manufacturer for different clinical situations
were 0.3-4 mU/1 for healthy individuals with no evidence of thy-
roid disease, euthyroidism < 4 mU/1, preclinical hyperthyroidism
< 0.5 mU/l, hyperthyroidism < 0.2 mU/1 (mostly < 0.1 mU/1), hy-
pothyroidism > 4 mU/1.
Magic Lite TSH hs, ClBA-Corning GmbH, Fermvald, Germany.
This test is an immunoluminometric assay using an acridinium
compound as label and magnetic microparticles as solid phase. The
calibration principle is identical with that of the BeriLux test and
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uses a lot specific master curve with two point calibration for each
run. The euthyroid range was declared as 0.25-4.5 mU/1, deter-
mined from 241 clinically euthyroid subjects. The euthyroid range
established in the laboratory was 0.2-3.5 mU/1.
Ultrasensitive TSH, Abbott Diagnostic^ Wiesbaden-Delkenheim,
Germany. The method is automated for the Abbott IMx and is a
microparticle based immunoenzymometric assay with alkaline
phosphatase and 4-methylumbelliferyl phosphate as substrate. The
detection is based on reflected fluorimetric. Samples from 405 ap-
parently healthy individuals gave rise to a euthyroid range from
0.32-5 mU/1 thyrotropin (2.5-97.5 percentiles). Hyperthyroid pa-
tients (n = 39) gave values < 0.2 mU/1 and 32 hypothyroid sub-
jects had values above 8 mU/1.
Pat ient groups studied
A total of 408 individuals was included in the study. These were
divided into the following groups according to clinical diagnosis:
140 euthyroid, 116 hyperthyroid (including 20 \vith subclinical hy-
perthyroidism [blunted thyroliberin-response]), 86 hypothyroid, 26
non-thyroidal illness and 30 with thyroid cancer.
Tab. la Functional sensitivity data from all centres for both the
test and comparison methods
German centre
Panel member
Serum 1
Serum 2
Serum 3
Serum 4
Serum 5
Serum 6
Serum 7
Austrian centre
Panel member
Serum 1
Serum 2
Serum 3
Serum 4
Serum 5
Serum 6
Serum 7
French centre
Panel member
Serum 1
Serum 2
Serum 3
Serum 4
Serum 5
Serum 6
Serum 7
Abbott Ultra II
Mean CV
thyrotropin (%)
(mU/1)
0.010 28.8
0.020 21.0
0.040 15.1
0.050 9.11
0.080 8.11
0.110 6.50
0.150 4.59
Abbott Ultra II
Mean CV
thyrotropin (%)
(mU/1)
0.010 65.7
0.020 23.6
0.040 18.0
0.060 16.9
0.080 8.13
0.110 11.0
0.115 6.67
Abbott Ultra II
Mean CV
thyrotropin (%)
(mU/1)
0.020 78.3
0.030 22.6
0.050 15.1
0.070 7.82
0.090 11.7
0.120 9.27
0.150 4.99
BeriLux
Mean
thyrotropin
(mU/1)
0.022
0.039
0.067
0.091
0.119
0.164
0.214
Dynotest
Mean
thyrotropin
(mU/1)
0.033
0.052
0.108
0.118
0.153
0.203
0.279
Abbott Ultra
Mean
thyrotropin
(mU/1)
0.020
0.040
0.070
0.090
0.120
0.150
0.210
CV
28.0
18.0
18.2
16.0
11.4
9.88
11.7
CV
34.7
36.3
44.8
21.3
13.4
11.4
10.3
*
CV
79.6
76.6
49.4
32.5
19.5
18.6
16.5
The thyroid cancer patients were under thyroxinc therapy (100-
190 μξ/d - mean 150 μg/d) (Euthyrox, Merck) or a combination
of 150 μg thyroxine and 20 μg triiodothyronine per day (Novothy-
ral, Merck).
A euthyroid status was assumed when the sonographic picture was
normal, the thyroid analytes thyrotropin and free thyroxine lay
within the euthyroid reference range and the patient had no symp-
toms of a thyroid disorder.
Procedures used
Precision
Between-run-precision was determined according to the ECCLS
format using three IMx Ultrasensitive hTSH II assay controls and
three human based serum panels. Samples were tested in duplicate,
once a day on each of ten days. Within-run-precision was per-
formed on 20 replicates of each of three assay controls.
Tab. Ib Summary of between-run precision for the test and com-
parison methods
German cenfre
Control Serum
Low control
Medium control
High control**
Assay panel 1
Assay penel 2
Assay panel 3
Austrian centre
Control serum
Low control
Medium control
High control**
Assay panel 1
Assay panel 2
Assay panel 3
French centre
Control serum
Low control
Medium control
High Control**
Assay panel 1
Assay panel 2
Assay panel 3
Abbott Ultra II
Mean CV
thyrotropin (%)
(mU/1)
0.25 6.8
6.02 5.2
28.6 6.5
0.07 11.1
1.47 5.8
30.5 8.7
Abbott Ultra II
Mean CV
thyrotropin (%)
(mU/1)
0.24 5.3
5.96 5.7
27.1 12.6
0.05 15.5
1.40 5.3
31.7 6.5
Abbott Ultra Π
Mean CV
thyrotropin (%)
(mU/1)
0.27 5.9
6.29 4.0
28.6 6.6
0.08 8.5
1.45 3.6
28.9 6.3
BeriLux
Mean
thyrotropin
(mU/1)
0.44
9.56
48.9
0.08
1.89
30.8
Dynotest
Mean
thyrotropin
(mU/1)
0.4
9.05
45.1
***
1.56
23.3
Abbott Ultra
Mean
thyrotropin
(mU/1)
0.26
6.57 -
56.3
0.10
1.69
29.5
CV
(%)
7.4
11.6
17.3
17.5
11.6
14.6
CV
(%)
7.1
5.6
4.6
***
9.4
17.0
*
CV(%)
13.0
4.0
3.5
32.8
5.0
4.4
Key: * The French site compared the new (Ultra II) TSH-Test with
its predecessor (Ultra) in this experiment. Data from the test kit
(CIBA-Corning Magic-Lite) used for the rest of the study were not
available (see I.e. (4) for characteristics of this kit).
Key: * The French site compared the new (Ultra II) TSH-Test with
its predecessor (Ultra) in this experiment. Data from the test kit
(CIBA-Corning Magic-Lite) used for the rest of the study were not
available (see 1. c. (4) for characteristics of this kit).
** The nominal concentration of this serum was 30 mU/1 thyrotro-
pin for the Ultra II test. A separate serum with a nominal value of
50 mU/1 thyrotropin was used for the comparison tests.
*** No results were obtained for this serum due to wrong labels
on the test serum bottles.
Apart from the high control, identical materials were used for test
and comparison assays.
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Analytical sensitivity
The potential lower detection limit of the assay was estimated as
follows: The zero calibrator was set up tenfold, the remaining five
calibrators in duplicate and the standard curve plotted from the
results. The potential lower limit of detection was calculated as the
concentration on the standard curve equivalent to the mean zero-
calibrator rate plus two standard deviations of the zero-calibrator
rate. A total of twelve independent runs was performed to deter-
mine the analytical sensitivity.
Functional sensitivity
Seven panel members were prepared from human serum containing
very low concentrations of thyrotropin. Each of these panels was
run in singlicate — i.e. under routine conditions — on each often
0.001
0.001 0.01
0.005 0.05
Thyrotropin (Behring BeriLux TSH) [mU/l]
Fig. la Data from the German centre.
The data from all samples are plotted on the graph, using a double
logarithmic scale because of the skewed distribution of the mea-
sured concentrations. This presentation also highlights the samples
with low thyrotropin concentrations. The Spearman rank correla-
tion coefficient was 0.948 for the 108 samples used. The house-
internal kit was plotted on the abscissa, the kit under test on the
ordinate. The equation for the regression line was log(y) = 0.997
log(x).
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Fig. Ib Data from the Austrian centre.
The data were presented as in figure la. The Spearman rank correlation coefficient was 0.978
for 106 samples used. The regression line equation was log(y) = 0.981 log(x) H- 0.009.
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0.001 *p6.
0.001 0.01
0.005 0.05 0.5 50
Thyrotropin (Ciba-Coming hs TSH) [mll/l]
Fig. Ic Data from the French centre.
The data were presented as in figure la. The Spearman rank correlation was 0.989 and the equation
for the regression line: log(y) = 0.987 log(x) - 0.002 for the 96 cases.
Tab. 2a Statistical data from the German centre for all three groups of patients
Euthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
2.5th percentile
97.5lh percentile
Hyperthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
95lh percentile
Not detectable
Hypothyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
5th percentile
n = 48
41 years
Ultra-II TSH (x)
1.01
0.74
0.14
3.51
0.20
3.40
n = 49
57 years
Ultra-II-TSH (x)
0.020
Not detectable
Not detectable
0.225
0.085
36/49
n = 30
57 years
Ultra-II TSH (x)
18.6
8.35
4.00
112
4.10
a = 0.051 b = 0.810 r = 0.825
Mean age: 40 years
Berilux TSH (y)
1.18
0.94
0.20
3.78
0.24
3.62
Calculation of a, b & r not done
Mean age: 54 years
Berilux TSH (y)
0.012
Not detectable
Not detectable
0.100
0.051
21/49
a =1.86 b = 0.717 r - 0.988
Mean age: 54 years
Berilux TSH (y)
23.3
9.37
5.06
156
5.27
Key: All concentrations are in mU/1.
The number of samples which were below the detection limit in
each assay in the hyperthyroid patients is given in the last row of
the data for this group. No regression line was constructed for this
group as too many values lay below the assay detection limit.
The relevant percent!les are given to allow an estimate for any
overlap between groups.
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days. The mean and coefficient of variation for each panel serum
were calculated. The functional sensitivity was recorded visually
on precision profile plots (see Results for details).
Recovery^ and linearity
Recovery and linearity were checked in one laboratory using addi-
tive and dilution techniques.
Statistics
Parametric statistics were used in all cases except the regression
analysis of all detectable samples (310/408 samples), where a
double logarithmic transformation of data was performed before
performing the Spearman rank correlation between in-house test
and the IMx Ultrasensitive hTSH II assay.
Results
Analytical sensitivity
The results from the 12 runs (see above) gave results
ranging from 0.004 and 0.013 mU/1, the mean value be-
ing 0.008 mU/1. In comparison, the corresponding mean
value from the Abbott Ultrasensitive hTSH (the prede-
cessor to the assay under evaluation) was 0.026 mU/1
(range 0.019-0.036).
Functional sens i t iv i ty
Table la shows the results for the seven test panel sera
for both the Abbott Ultrasensitive hTSH II and for the
kit used for comparison. The results show that the kit
under evaluation fits the definition of a 'third genera-
tion' thyrotropin assay according to Nicoloff & Spencer
(1). Only one of the kits used for comparison fulfils this
definition (BeriLux). The results must be treated with
care, as the evaluation of the functional sensitivity was
performed on pooled sera and not from single sera from
hyperthyroid/thyrotoxic patients.
Precision
Table Ib summarises the inter-assay (im)precision data.
The kit under test showed better precision on the
whole, when compared with the test kits used for
comparison. This may very well be a result of the
Tab. 2b Statistical data from the Austrian centre for all three groups of patients
Euthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
2.5lh percentile
97.5th percentile
Hyperthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
95th percentile
Not detectable
Hypothyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
5th percentile
n = 48
59 years
Ultra-II TSH (x)
1.49
1.48
0.09
2.98
0.59
2.78
n = 39
37 years
Ultra-II TSH (x)
0.020
0.020
Not detectable
0.250
0.060
23/39
n = 32
44 years
Ultra-n TSH (x)
32.0
23.2
3.80
100
7.20
a = 0.089 b = 0.881 r = 0.927
Mean age: 59 years
Dynotest TSH (y)
1.59
1.52
0.11
3.08
0.60
3.04
Calculation of a, b, & r not done
Mean age: 40 years
Dynotest TSH (y)
Not detectable
Not detectable
Not detectable
Not detectable
Not detectable
39/39
a = -4.25 b = 1.08 r = 0.952
Mean age: 41 years
Dynotest TSH (y)
33.6
26.6
4.97
81.3
7.50
Key: All concentrations are in mU/1.
The number of samples which were below the detection limit in
each assay in the hyperthyrpid patients is given in the last row of
the data for this group.
The relevant percentiles are given to allow an estimate for any
overlap between groups.
The correlation data for the hyperthyroid patients could not be cal-
culated as all data from the Dynotest lay below the detection limit
of the assay (0.03 mU/1).
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full automation combined with'the quality of the anti-
bodies used.
Recovery and l inear i ty
Thyrotropin was added to three sera with endogenous
thyrotropin concentrations of 1.62, 2.38 and 4.36 mU/1,
the amounts added being 20, 40, 60 and 80 mU/1. The
recovery (expected value) lay between 91 and 111%
(mean value 100%).
Two sera, one with 0.86 mU/1 and one with 49.2 mU/1
were diluted with a serum with a thyrotropin concentra-
tion under 0.01 mU/1 in five steps between 1 : 1.125 and
1 : 10. The values found ranged between 89 and 117%
(mean value 104%) of the expected values.
Assay comparison
The assays were compared in different concentration
ranges, i.e. with hyper-, eu- and hypothyroid patient
sera. In addition, patients with thyroid cancer and non-
thyroidal illness were investigated at one test centre. The
results were interpreted both in terms of analytical and
clinical performance, in order to estimate misclassifica-
tion errors and where possible the source of error. The
in-house kit results are plotted on the abscissa, the kit
under test on the ordinate. f
Figures la-lc show the comparison between the kits
used, using a double logarithmic scale for the data sets
in each case. Tables 2a-2c show the corresponding data
for euthyroid, hyper- and hypothyroid subjects. Table 2d
shows the results for the thyroid cancer patients and
those with non-thyroidal illness.
Results which gave rise to clinically discordant diagno-
ses were only found in two cases. One patient classified
as having a "non-thyroidal illness" had a thyrotropin
concentration in the Abbott test of 6.4 mU/1, in the Dy-
notest 1.4 mU/1. The corresponding free thyroxine and
free triiodothyronine concentrations were 5.2 pmol/1 and
2.0 pmol/1, respectively and lay in the hypothyroid
range. The second case, a patient with "subclinical hy-
Tab. 2c Statistical data from the French centre for all three groups of patients
Euthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
2.5th percentile
97.5% percentile
Hyperthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
95th percentile
Not detectable
Hypothyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
5th percentile
n = 44
42 years
Ultra-II TSH (x)
1.21
1.04
0.07
3.11
0.21
3.08
n = 28
55 years
Ultra-II TSH (x)
0.006
0.020
Not detectable
Not detectable
0.035
24/28
n = 32
44 years
Ultra-II TSH (x)
17.4
11.4
3.82
86.7
4.10
a = 0.078 b = 0.895 r = 0.961
Mean age: 45 years
Corning TSH (y)
1.26
1.11
0.08
3.30
0.24
3.20
Calculation of a, b & r not done
Mean age: 55 years
Corning TSH (y)
Not detectable
Not detectable
Not detectable
Not detectable
0.057
23/28
a = -4.24 b = 1.08 r = 0.952
Mean age: 41 years
Corning TSH (y)
19.9
14.8
4.03
100
4.30
Key: All concentrations are in mU/1.
The number of samples which were below the detection limit in
The< relevant percentiles are given to allow an estimate for any
overlap between groups.· —~ w^wwuvii unlit ill UYCIlap UCIWCCII lUU S
each assay m the hyperthyroid patients is given in the last row of The correlation data for the hyperthyroidjpatients could not be calr
the data tor this group. ciilateH ** th* maWiK, ^f Α»*» Λ™ uXU, ~^~Α~ u„ i^i™ *Uculated as the majority of data from both methods by below the
detection limit of the assay.
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perthyroidism" had a thyrotropin concentration of 0.25
mU/1 in the Abbott test and < 0.03 mU/1 in the Dy-
notest, the corresponding free thyroxine and free triiodo-
thyronine concentrations being 23.4 pmol/1 and 5.2
pmol/1, respectively, i.e. both in the euthyroid range.
Full concordance of results, as seen from the clinical
diagnostic point of view, was achieved in all other pa-
tients with defined thyroid function.
A point to note was the relatively poor correlation be-
tween both kits tested for the non-thyroidal illness pa-
tients. These patients were often undergoing intensive
care with treatment involving many drugs and infusions,
which may account for the poor comparability of results.
Discussion
The need for thyrotropin assays with low detection lim-
its and good analytical and diagnostic sensitivity has led
to continual methodological improvements and the in-
troduction of such terms as 'first', 'second' and 'third'
generation assays, depending upon the lower detection
limit and (im)precision data of the tests in question
(1—4). The aim of the producer of kits to measure thyro-
tropin must be to bring a kit onto the market which ful-
fils the actual clinical and analytical needs (5, 6). In the
case of thyroid illness, it has been difficult to develop
methods able to discriminate fully between eu- and hy-
perthyroidism, especially using an enzyme label. By
combining a microparticle technology with fluorescence
enhancement and a fully automated test procedure, (ex-
cluding the pipetting of sample), it has become possible
to reach the lower detection limit reserved for lumines-
cence, time-resolved fluorescence and radioisotopic la-
bels. In addition, the fluorescence detection overcomes
the typical limits set by the Beer-Lambert law with col-
orimetric measurements using a single wavelength for
detection.
Although the definition of the lower detection limit or
analytical sensitivity of an immunoassay was published
many years ago by Rodbard (7) and Elans (8), there has
been much discussion about this point which has led to
a certain amount of confusion. Although the method
used in this study for defining the lower detection limit
of the assay differs from that of Rodbard, it is equally
Tab. 2d Statistical data from the Austrian centre for the sub-clinical hyperthyroid, non-thyroidal illness
and thyroid cancer patients
Non-thyroidal illness
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
Clinically sub-hyperthyroid
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
Non-detectable
Thyroid cancer
Regression data
Median age:
Mean (mU/1)
Median (mU/1)
Minimum value
Maximum value
Non-detectable
n = 17
Not given
Ultra-II TSH (x)
1.10
0.60
0.01
6.40
n = 20
40 years
Ultra-II TSH (x)
0.020
0.008
Not detectable
0.245
12/17
n = 30
40 years
Ultra-II TSH (x)
Not detectable
Not detectable
Not detectable
0.060
19/30
a = 0.166 b = 1.077 r = 0.461
Mean age: Not given
Dynotest TSH (y)
0.86
0.84
0.10
2.38
Calculation of a, b & r not done
Mean age: 43 years
Dynotest TSH (y)
Not detectable
Not detectable
Not detectable
0.080
16/17
Calculation of a, b & r not done
Mean age: 43 years
Dynotest TSH (y)
Not detectable
Not detectable
Not detectable
0.060
26/30
Key: All concentrations are in mU/1.
The number of samples which were below the detection limit in
each assay in the hyperthyroid patients is given in the last row of
the data for this group.
The relevant percentiles are given to allow an estimate for any
overlap between groups.
The correlation data for the hyperthyroid patients could not be cal-
culated as all data from the Dynotest lay below the detection limit
of the assay (0.03 mU/1).
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valid statistically. The actual lower detection limit, as
defined by the functional sensitivity is a practical rather
than a theoretical approach to the problem, although dif-
ferent authors give different performance criteria for the
estimation of the functional sensitivity (9—11).
Tables 2a-2d also show the median ages of the groups
under study in the three centres. It can be seen that the
euthyroid patients in the Austrian study were signifi-
cantly older than those in the other centres. The mean
and median thyrotropin concentrations were higher than
in the other centres and were more normally distributed
(mean/median » 1.0). The hyperthyroid patients were
younger in the Austrian centre than in the other two
centres. The hypothyroid patients were older in the Ger-
man centre than in either of the other two centres.
The good correlation data in the eu- and hypothyroid
ranges shows the comparability with other commercial
available tests for thyrotropin. The relatively poor cor-
relation in the non-thyroidal illness group (tab. 2d)
may come from the limited concentration range of
thyrotropin in this group as well as the low number
of samples tested (n = 17). The clinical discrimination
of samples was excellent, with only 2 aberrant values
(see above).
Both the analytical and functional sensitivity of the Ab-
bott Ultrasensitive hTSH assay place it in the category
of a 'third generation' test (1), thus allowing for discrim-
ination between eu- and hyperthyroid patients at the
highest level of commercially available analytical testing
at the present time.
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External Quality Assessment: Currently Used Criteria
for Evaluating Performance in European Countries,
and Criteria for Future Harmonization
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Summary: A questionnaire was circulated to European countries seeking information on the criteria used for
acceptable performance in external quality assessment schemes. Responses were obtained from 21 countries. Fixed
limits are used in 13 countries but the basis for these varies widely and includes clinical decision making, biological
variation, views of experts, the state-of-the-art, and combinations of approaches. Variable limits based upon statisti-
cal analysis of the performance attained are used in 8 countries. The many advantages of harmonization in Europe
have prompted the development of criteria based upon within- and between-subject biological variation for use in
schemes which circulate single specimen challenges. Currently used criteria, which show much diversity, are com-
pared with these proposals, and the empirical nature of the majority of the former is demonstrated.
Introduction countries. On the one hand this is un advantage, because
This work was done by a Working Group which was il allows lhc E(^AS to be adaPted lo lhe sPccial Pre"
formed in 1994, as consequence of various European Vailin8 situalion in Mch °° ** On the other hand U
EQAS-organizers' meetings held under the umbrella creates difficulties with respect to the ongoing sociakind
of the CEC Standards, Measurements and Testing Pro- economic harmonization efforts within Europe and pro-
gramme (formerly BCR). The aim of the Working vents the setting up of a uniform health care policy.
Group is to collaborate in the harmonization of results We stress that this paper is not related to the possible
in the field of laboratory medicine; it acts on a volun- role of EQAS for accreditation purposes. Rather, it
tary basis, in conjunction with three other Working asserts that the main objective of EQAS is to help
Groups coordinated by Dr. Adam Uldall, of Herlev laboratories in the creation of quality and to promote
Hospital, Denmark. transferability of results among European countries.
At present, external quality assessment schemes (EQAS) The two principal aims of EQAS are lo define target
exist in the field of laboratory medicine in many coun- values, and to define the limits for acceptance. The
tries. Most of these are intended to assist individual target values should be assigned from reference meth-
laboratories to continuously monitor their performance, ods, but as only a few schemes follow these principles,
and to compare it with that of other laboratories, target values arc derived from the statistics of each sur-
whereas others may be intended primarily for accredita- vey (overall or method-group mean). Although the rele-
tion/licensing purposes. Additionally, EQAS may moni- vant differences among countries are pointed out in this
tor the quality of commercial analytical systems, rea- paper, they do not constitute the basis of this work. The
gents and test kits, and they help manufacturers to reason for this decision is that to promote changes on
achieve a better harmonization of the results from these this subject implies that the design of programmes must
different analytical techniques. Owing to these different be reviewed (management Field), and the aim of the
aims and its different stages of development, the design Working Group is primarily intended to stimulate
of EQAS varies to a great extent in individual European thought (the inherent educational role of current EQAS).
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In particular, it has been realized in the recent years that
a major obstacle to the harmonization of European
EQAS is the different acceptance of limits used in indi-
vidual countries. These limits are the interval within
which the results of an individual laboratory must lie to
be considered as acceptable. In consequence, the Work-
ing Group tried to develop a concept for deriving accep-
tance limits for EQAS which should be generally appli-
cable all over Europe. Before doing this, the group felt
it of great importance to have a picture of currently used
limits and to understand the reasons underlying their
generation. For this purpose, a questionnaire was sent to
European EQAS organizers, seeking information on the
criteria for setting limits and the actual numbers used
for general biochemical quantities. Data from 21 coun-
tries have been received and are presented here. In addi-
tion, the Working Group outlines a concept for deriving
EQAS acceptance limits from biological variation,
which is intended for use as a common European work-
ing basis for currently conducted schemes.
Results and Discussion
The information provided reveals two main types of cri-
terion for defining EQA limits:
i) criteria based on biological variation, opinions of ex-
perts, "fixed" state-of-the-art, or combinations of these,
leading to "fixed limits";
ii) statistical criteria applied to the outcome of each sur-
vey, leading to "variable limits" (real state-of-the-art
limits) (tab. 1).
i) Fixed limits are used in 13 out of the 21 countries
which responded to the questionnaire. But, as addressed
Tab. 1 Criteria for defining limits in EQAS
Abbreviations:
CVbi = within-subject coefficient of variation; CVwlab = within-
laboratory coefficient of variation; P95 = 95th percentile; clin =
clinicians; CCV = chosen coefficient of variation
Country
Denmark
Netherlands
Belgium
Germany
Czech Republic
Luxembourg
Finland
(labquality)
Norway
Switzerland
Croatia
Lithuania
Ireland
United Kingdom
Fixed limits
3 (1/2 CVbi)
3 (1/2 CVbi)
Biology
3 (CVwlab)
3 (CVwlab)
3 (CVwIab)
Experts, P95
Labquality
Clin, analysts
2 (CVwlab)
CCV
CCV
Country
Italy
(Lombardia)
Spain
France
Portugal
Iceland
Greece
Russia
Sweden
Variable
limits
?95
P95
F95, 99
?95, ?99
Murex
__
_
above, the criteria for deriving them vary to a great ex-
tent:
- Denmark (DK) recommends three times half the
within-subject biological variation (sO, using the desir-
able analytical standard deviation .goal (sa) for routine
methods, which is sa < 0.5 Sj (1, 2). But, being well
aware that many routine methods currently do not meet
this desirable goal for analytical standard deviation (e. g.
methods for sodium, chloride, calcium, protein), the re-
sulting EQA limits are meant as targets to be reached in
the future rather than for judgement of current perfor-
mance.
— The Netherlands (NL) use principally the same ap-
proach as described above for Denmark. As in Denmark,
some of the limits are used as an aim to be strictly ap-
plied only in the future. On the other hand, lower limits
are used for some quantities when the respective meth-
ods perform much better than required by strict adher-
ence to desirable analytical goals (e. g. lactate dehydro-
genase, aspartate aminotransferase and alanine amino-
transferase). A peculiarity of this EQA scheme is that, in
contrast to the generalized approach of single specimen
challenges, they conduct a multispecimen testing
scheme with the establishment of the laboratory mean
and standard deviation, computed from eight results ob-
tained in each time period. Thereafter, the statistically
expected percentage (equal to the score of the partici-
pant) of results residing in the range of target ± three
times the tabulated within-subject biological variation,
is calculated (3).
— Belgium (BE) also uses limits based on biological
variation, while respecting desirable analytical goals ac-
cording to the combined allowable bias and standard de-
viation limits as proposed by Fräser & Hyltoft (4). How-
ever, for quantities where current analytical performance
does not meet these goals, the desirable EQA limits are
substituted by practical ones, derived from the state-of-
the-art, as proposed in the document produced by a
working group of EGE-Lab (5).
- Germany (DE) uses limits which are three times the
maximum within-laboratory standard deviation (s),
which themselves were derived from the respective ref-
erence intervals (6); but, additionally, take into account
the analytical state-of-the-art at the time when the Ger-
man guidelines became mandatory (7). Unique in the
German scheme is the use of reference method target
values for many quantities which, in turn, sometimes
necessitates higher EQA limits than in other countries.
- The Czech Republic and Luxembourg have adopted
the German system.
— Finland (FI) (and also Norway which participates in
the Finnish scheme) and Switzerland (CH) use accept-
able limits set by experts, which take account of the
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clinical decision, the biological variation and the 95%
in limit analytical state-of-the-art. (It should be noted
here that since January 1995 Denmark, Norway, Iceland
and Finland have been using mutual limits).
- Croatia (CR) reported the use of limits which were
twice the maximum within-laboratory CV, without ex-
plaining how the respective CV data were derived.
- Lithuania reported the use of fixed limits, but again
without explaining the underlying concept.
- The United Kingdom (GB) uses average CV values
based on historical observed data from the scheme,
established around 20 years ago (CCV) (8), for partici-
pant assessment.
- Ireland (IE) has adopted the GB system, but classifies
participants as poor only when their results are "far
away" from those of the majority.
ii) eight countries base their limits for EQA on the actual
outcome of each survey. Therefore, the values given in
tables 2—4 represent an average of results from recently
conducted surveys.
- Spain (ES), Italy (IT) (Lombardia), France (FR) and
Portugal (PT) judge all results acceptable which fall
within the 95% or 99% interval (depending on the quan-
tity) around the mean.
- Iceland (IS) participates in a commercial scheme
(Murex Diagnostics) which uses statistical acceptance
criteria similar to those described above, but the actual
limits were not reported.
— The EQA scheme in Russia is merely informative
without using acceptance limits.
— Sweden started an EQA scheme as recently as 1992
and has not yet formulated acceptance limits; the same
is true for Greece.
The limits reported by the different countries are pre-
sented in tables 2—4 (country grouping is identical to
that in tab. 1). It should be noted here that most schemes
work with single analysis of specimens and participant
assessment in each survey (except the Netherlands and
the United Kingdom, which use cumulative survey data
for performance assessment). As mentioned above, no
Tab. 2 Currently used European EQA limits (given in % deviation from the target)
Na Cl Ca Mg Albumin Protein Glucose K
a
 same limits for Czech Republic and Luxembourg
b
 same limits for Norway
Creatinine
Denmark
Netherlands
Belgium
Germany3
Finland3
Switzerland
Croatia
Lithuania
United Kingdom
Spain
Italy
France
Portugal
0.9
0.9
2.0
6.0
3.0
2.0
3.0
3.0
1.6
6.6
2.0
3.5
2.5
2.1
2.1
3.0
6.0
3.0
3.0
4.0
3.0
2.2
10.0
4.0
4.0
6.0
2.7
2.7
4.5
10.0
3.0
4.0
5.0
2.0
4.0
10.0
5.5
4.6
7.0
3.5
3.3
9.5
12.0
5.0
4.0
—
-
10.0
-
—
12.0
—
4.2
4.2
6.2
18.0
5.0
6.0
—3.0
7.5
14.0
4.0
10.0
—
4.2
4.2
5.5
9.0
5.0
3.0
8.0
3.0
3.9
9.2
4.0
10.0
5.0
6.6
10.0
14.0
15.0
5.0
7.0
5.0
5.0
7.7
9.8
6.0
11.0
6.0
8.2
7.2
8.0
8.0
3.
3.0
5.0
2.0
2.9
7.4
3.0
6.8
5.0
6.6
6.6
8.0
18.0
5.0
15.0
10.0
5.0
8.9
14.0
8.8
11.0
12.0
Tab. 3 Currently used European EQA limits (given in % deviation from the target)
Denmark
Netherlands
Belgium
Germany3
Finland
Switzerland
Croatia
Lithuania
United Kingdom
Spain
Italy
France
Portugal
Cholesterol
8.1
8.1
8.4
18.0
5.0
3.0
10.0
7.0
7.6
9.8
5.5
16.5
5.0
Pi
12.0 '
—
14.0
15.0
5.0
10.0
10.0
5.0
7.8
12.0
9.5
—8.0
Lithium
__
5.0
10.0
12.0
5.0
6.0
—
—11.0
22.0
—
10.0
—
Lactate
dehydrogenase
12.0
3.0
15.0
21.0
10.0
15.0
20.0
7.0
13.0
17.0
1 0.0
20.0
16.0
Urate
13.0
10.0
15.0
18.0
5.0
10.0
10.0
7.0
7.7
15.0
8.0
16.0
9.0
Alkaline
phosphatase
10.0
8.0
10.0
21.0
10.0
15.0
20.0
7.0
15.0
22.0
18.0
20.0
29.0
Amylase
11.0
10.0
17.0
21.0
10.0
20.0
—10.0
11.0
56.0
—25.0
—
a
 same limits for Czech Republic and Luxembourg
b
 same limits for Norway
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data are shown in tables 2-4 for the Czech Republic,
Luxembourg, Norway and Ireland because they have
adopted values from other countries. In addition, Russia,
Sweden, Greece and Iceland are not represented, either
because acceptance limits are not used in those coun-
tries, or because they were not reported. Further, quanti-
ties have been arranged according to increasing biologi-
cal variation.
This principle was also used for creating figure 1, which
is intended to give a rapid overview of the limits without
indicating the countries applying them. In figure 1 also,
the values derived from the concept of the Working
Group (see below) are included, using the symbol "Δ".
As can be seen from figure 1 and tables 2-4, the cur-
rently used European EQA limits show relatively high
variation for nearly all quantities. For example, for so-
dium they vary between 0.9% in Denmark and 6.6% in
Spain (tab. 2), for cholesterol from 3% in Switzerland
to 18% in Germany (tab. 2), and for urea from 5% in
Finland to 24% in Germany (tab. 4). The same wide
disagreement may be seen in figure 2, where data have
been grouped according to the typo bf limits used: fixed
limits on the left and variable limits on the right.
This is not surprising because the different EQA
schemes have different aims and are conducted under
different constraints. Countries basing their limits on
biology (e. g. Denmark and The Netherlands) have nar-
row limits for analytes with a low biological variation
and wide limits for analytes with high biological varia-
tion. But the former in particular are primarily intended
as goals to be reached in the future. In practice, they are
often widened for quantities with a narrow biological
Tab. 4 Currently used European EQA limits (given in % deviation from the target)
Denmark
Netherlands
Belgium
Germany
Finland0
Switzerland
Croatia
Lithuania
United Kingdom
Spain
Italy
France
Portugal
Urea
19.0
19.0
16.0
24.0
5.0
7.0
7.0
7.0
5.7
10.0
9.5
16.0
6.0
Aspartate
amino-
transferase
22.0
7.0
16.0
21.0
10.0
15.0
20.0
7.0
12.0
17.0
10.0
20.0
12.0
Bilirubin
34.0
33.0
24.0
24.0
10.0
30.0
10.0
—
19.0
28.0
—
15.0
13.0
γ-Glutamyl-
transferase
22.0
18.0
15.0
21.0
10.0
15.0
20.0
10.0
13.0
18.0
13.0
20.0
11.0
Triacyl-
glycerol
34.0
33.0
20.0
21.0
10.0
10.0
10.0
7.0
—
14.0
8.5
15.0
7.0
Alanine
amino-
transferase
41.0
10.0
20.0
21.0
10.0
15.0
20.0
7.0
15.0
17.0
13.0
20.0
11.0
Fe
48.0
30.0
—
21.0
10.0
12.0
10.0
5.0
15.0
16.0
9.0
20.0
7.0
Creatine
kinase
62.0
63.0
20.0
24.0
10.0
20.0
20.0
7.0
18.0
52.0
16.0
25.0
14.0
a
 same limits for Czech Republic and Luxembourg
b
 same limits for Norway
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Fig. 2 Interlaboratory variation limits for cholesterol.
variation, in order to reach realistic acceptance figures
which can be presented to the participants (Belgium
and The Netherlands). Germany, with a mixture of
biology and state-of-the-art limits, as well as providing
a scheme acceptable by the health insurance system,
has to use relatively large limits, except for quantities
where the current analytical performance is much bet-
ter than required by biology (e.g. enzyme activity
assays). EQA limits set by experts (Finland and Swit-
zerland) take account of current analytical perfor-
mance, in turn leading to relatively wide limits for
quantities with narrow biological variation like so-
dium, albumin or calcium. On the other hand, they
show a tendency to set a general upper EQA limit
which is 10% in the case of Finland. Interestingly,
Lithuania follows the Finnish limits very closely, pos-
sibly because these two countries are geographically
close. Croatia, did not reported the basis of its limits,
and sets an upper limit of 20%.
Among the countries using variable limits, reflecting the
"real" state-of-the-art, Spain generally shows the highest
limits, while Italy mostly shows the lowest. This might
be due to the different statistical levels applied for ac-
ceptance, the wide diversity of procedures used or the
different types of laboratories participating (e. g. studies
made in Spain revealed that in certain areas all laborato-
ries use the same procedures with a consequent general
agreement of results, and that the group of public
laboratories had less variation than the overall group; in
the case of Italy only one specific geographical area has
submitted data to our questionnaire), or the different
targets used (e. g. overall mean or group target). In addi-
tion, also in this group, there seems to be a tendency
for setting upper limits (e. gf in France, 20—25% for
enzymes). As pointed out above, the United Kingdom is
unique because performance is judged from cumulated
data, which mostly allows more narrow limits to be used
than in the other countries in this group. Other issues
such as common standardization (including calibrators,
control materials with minimum matrix effect, etc) and
reliable target values may also be addressed in this
context. But these considerations are beyond the scope
of this work.
The concept of the Working Group
Considering the data received, we believe that there is a
strong need for harmonization of EQA limits in Europe.
But, it is clear that harmonized European EQA limits
are only possible with a harmonized analytical design of
the schemes (e. g. single or multiple measurements, sin-
gle target or multiple targets, 95 or 99% confidence in-
terval).
Therefore, the Group first had to define the situation to
which their concept should be applicable. Because most
schemes use single measurements and certain cut-off
values for judgement of performance, the Working
Group restricted itself to this design. This does not mean
that the Working Group recommends this approach for
the future. On the contrary, it recommends development
of alternative EQA models (9), more appropriate for in-
structive purposes, but which are out of the scope of this
presentation. The model presented below, therefore, is
primarily intended as a realistic working basis for EQA
schemes as they are conducted today. In any case, the
Working Group is convinced that a theoretical concept
based on biology should be the starting point for deriv-
ing EQA limits for every situation. Moreover, EQA lim-
its have to be built on quality specifications for routine
methods. The Group therefore chose, as the principal
underlying concept for deriving EQA limits, the desir-
able specifications for routine method bias and random
error combined (5, 10), which are the sources of uncer-
tainty affecting a single analysis. Then, the desirable
EQA limits (or desirable maximum deviation of a partic-
ipant from the target = D%) can be expressed as fol-
lows:
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D < K X 0.5 CVi + 0.25~(CV? + CV*)1'2
K =1.65 or 2.33 for 95 or 99% acceptance
CVj = average within-subject biological variation
CVg = average between-subject biological variation
We preferred the use of coefficient of variation over
standard deviation because nearly all EQA schemes use
the former.
According to this formula, the percentage deviations of
a single analysis derived from biology (99% confidence
interval) for the quantities studied are shown in table 5.
Figure 1 shows that quantities with low biological varia-
tion (sodium, chloride, calcium and albumin) have nar-
row acceptance limits. At present very few countries
maintain interlaboratory variation within these restricted
intervals, but a general application of these limits would
spur manufacturers to develop improved analytical pro-
cedures. However, we emphasize that other mechanisms
Tab. 5 Percentage deviations of a single analysis derived from
biology (99% confidence interval)
Quantity Deviation
Na
Cl
Ca
Mg
Albumin
Total protein
Glucose
K
Creatinine
Cholesterol
Inorganic phosphate
Li
Lactate dehydrogenase
Urate
Alkaline phosphatase
Amylase
Urea
Aspartate aminotransferase
-Glutamyl transferase
Bilirubin
Triacylglycerol
Alanine aminotransferase
Fe
Creatine kinase
0.90
2.13
2.80
4.16
4.36
4.8
7.0
7.2
7.9
10.4
12.4
12.6
13.2
13.8
14.3
15.1
20.8
23.1
29.2
36.2
42.6
45.3
45.9
68.0
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